Physician profile
Christopher E Emond
NPI 1922273648
$2,588.69
in general payments reported to CMS, 2019-2025
12 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $40.71 · 2021: $76.28 · 2022: $116 · 2023: $199 · 2024: $217 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Travel and Lodging: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.59 |
| Travel and Lodging | $828.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,661.22 | 2020-2025 | Mako, Inspace, Aequalis Perform Reversed |
| Arthrex, INC. | $294.20 | 2019-2023 | |
| Mid-Atlantic Surgical Systems, LLC | $282.67 | 2024-2025 | |
| Innovation Technologies INC | $85.76 | 2022 | |
| Zimmer Biomet Holdings, INC. | $63.08 | 2021 | |
| Ferring Pharmaceuticals INC. | $61.67 | 2021-2025 | Euflexxa |
| Bioventus LLC | $33.02 | 2019 | |
| Ethicon US, LLC | $28.58 | 2023 | Vistaseal |
| Pacira Pharmaceuticals Incorporated | $24.85 | 2024 | Exparel |
| Vertex Pharmaceuticals Incorporated | $23.76 | 2025 | |
| Pacira Therapeutics, INC. | $18.24 | 2020 | |
| Medline Industries Lp | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Emond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.